Analysis
bioAffinity Technologies filed a Form S-1 registration statement with the SEC on June 12, followed by an amended S-1/A on June 16, to support a public offering built around its already-commercial flagship product: CyPath Lung, a noninvasive diagnostic test using flow cytometry to detect early-stage lung cancer in patients at high risk for the disease.
The clinical data behind CyPath Lung is genuinely strong for a noninvasive screening tool. In a published clinical trial, the test demonstrated 92% sensitivity, 87% specificity, 88% accuracy and a 99% negative predictive value in detecting lung cancer among high-risk patients with small, indeterminate lung nodules under 20 millimeters -- precisely the ambiguous, hard-to-diagnose case category where a reliable noninvasive test has the most clinical value, since these nodules often otherwise require invasive biopsy to resolve.
Unlike many biotech IPO candidates filing well ahead of any commercial revenue, bioAffinity's offering is backed by real, already-growing sales: the company reported nearly 300% year-over-year growth in CyPath Lung unit sales in April 2026, with management stating that full-year 2026 growth is exceeding the company's own internal projections. That commercial traction gives the IPO a materially different risk profile than a purely preclinical or early-trial biotech offering.
“What to watch next: bioAffinity's full-year 2026 revenue disclosure once available, and early results from the sputum-based detection trial at military medical centers.”
The company is also expanding its evidence base: a clinical trial detecting early-stage lung cancer via sputum samples, supported by the John P. Murtha Cancer Center Research Program, began enrolling its first patient in March 2026 across military medical centers -- a study that could extend CyPath's diagnostic reach to an even less invasive sample-collection method than the current test.
For healthcare investors, bioAffinity's combination of strong published clinical performance and genuine, accelerating commercial sales growth differentiates it from earlier-stage diagnostics IPOs still years from any revenue, making the offering a comparatively lower-risk way to gain exposure to the noninvasive cancer-diagnostics category. For founders in diagnostics and medtech, bioAffinity's approach -- proving commercial traction with an existing product before or alongside the IPO process, rather than relying purely on a pipeline story -- is a useful template for de-risking a public-offering narrative.
The bear case: nearly 300% growth off what may still be a relatively small commercial base doesn't guarantee the growth rate holds as CyPath Lung scales into a larger addressable market, and noninvasive diagnostics still face reimbursement and physician-adoption hurdles that can slow growth even with strong clinical data. What to watch next: bioAffinity's full-year 2026 revenue disclosure once available, and early results from the sputum-based detection trial at military medical centers.
